The dosage regimen of levamisole in cancer: is it related to efficacy and safety?

Int J Immunopharmacol. 1983;5(1):1-9. doi: 10.1016/0192-0561(83)90065-6.
No abstract available

Publication types

  • Review

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Adjuvants, Immunologic / therapeutic use
  • Agranulocytosis / chemically induced
  • Agranulocytosis / complications
  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms / complications
  • Breast Neoplasms / drug therapy
  • Dose-Response Relationship, Drug
  • Female
  • Finland
  • Head and Neck Neoplasms / complications
  • Head and Neck Neoplasms / drug therapy
  • Humans
  • Levamisole / administration & dosage*
  • Levamisole / adverse effects
  • Levamisole / therapeutic use
  • Lung Neoplasms / complications
  • Lung Neoplasms / drug therapy
  • Male
  • Mice

Substances

  • Adjuvants, Immunologic
  • Antineoplastic Agents
  • Levamisole